3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
13
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Colorectal Neoplasms
8
Melanoma
6
Head and Neck Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
cemiplimab
×
Gastrointestinal
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled